Casper Schalkwijk


Prof. Casper Schalkwijk studied chemistry at University Utrecht and graduated in biochemistry. At the same university he obtained his PhD in 1992. He did post-graduate training in endothelial cell biology at TNO-PG in Leiden. He was appointed in 1995 as assistant professor and staff member at the Department of Clinical Chemistry at the Vrije Universiteit Medical Cente in Amsterdam and from 2004 as associate professor. He has led the Vascular Unit. He moved to the Department of Internal Medicine at Maastricht University in 2005, where he is heading the Laboratory for Metabolism and Vascular Medicine (~15fte). He was appointed as Professor of Experimental Internal Medicine at the Faculty of Health, Medicine and Life Sciences (FHML) of Maastricht UMC+ in 2011.

His main research themes are obesity, insulin resistance, endothelial function and vascular complications. The importance of endothelial dysfunction for the development of diabetic complications is studied in epidemiological setting with the availability of several cohorts and with experimental ex-vivo -, animal - and cell work. He has led several clinical studies. A major aim of his programme is to deliver specific and sensitive diagnostic biomarkers for the identification of patients developing  type 2 diabetes and to identify patients with high risk of vascular complications. Robust analytical techniques for measurements of biomarkers with multi-array technology and with UPLC-MSMS are available. A second aim of his programme is to obtain insight in the pathophysiology of vascular complications in diabetes. His current studies focus mainly on the importance non-enzymatic glycation for the development of diabetes and diabetic complications. He discovered, as one of the first, the link between AGEs and vascular complications in individuals with and without diabetes. He is an (inter)nationally recognised expert in the field of glycation. His lab is one of the most renowned labs in this field.The work has been supported by several grants and is now granted by the Diabetes Fonds Nederland, EFSD, NWO, ZonMw and NVWA.

Department of Internal Medicine
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room number: 5.324
T: +31(0)43 388 21 86

  • 2022
    • Jin, S., Reesink, K. D., Kroon, A. A., de Galan, B., van der Kallen, C. J. H., Wesselius, A., Schalkwijk, C. G., Stehouwer, C. D. A., & van Greevenbroek, M. M. J. (2022). Complement factors D and C3 cross-sectionally associate with arterial stiffness, but not independently of metabolic risk factors: The Maastricht Study. Journal of Hypertension, 40(11), 2161-2170.
    • van der Heide, F. C. T., Foreman, Y. D., Franken, I. W. M., Henry, R. M. A., Kroon, A. A., Dagnelie, P. C., Eussen, S. J. P. M., Berendschot, T. T. J. M., Schouten, J. S. A. G., Webers, C. A. B., Schram, M. T., van der Kallen, C. J. H., van Greevenbroek, M. M. J., Wesselius, A., Schalkwijk, C. G., Schaper, N. C., Brouwers, M. C. G. J., & Stehouwer, C. D. A. (2022). (Pre)diabetes, glycemia, and daily glucose variability are associated with retinal nerve fiber layer thickness in The Maastricht Study. Scientific Reports, 12(1), [17750].
    • Top, W. M. C., Lehert, P., Schalkwijk, C. G., Stehouwer, C. D. A., & Kooy, A. (2022). Effect of metformin on arginine and dimethylarginines in patients with advanced type 2 diabetes: A post hoc analysis of a randomized trial. Diabetes Obesity & Metabolism, 24(10), 1983-1988.
    • Janssen, L. E. F., Simons, N., Simons, P. I. H. G., Schaper, N. C., Feskens, E. J. M., van der Ploeg, L. M. C., Van den Eynde, M. D. G., Schalkwijk, C. G., Houben, A. J. H. M., Stehouwer, C. D. A., & Brouwers, M. C. G. J. (2022). Effects of fructose restriction on blood pressure: Secondary analysis of a double-blind randomized controlled trial. Clinical Nutrition ESPEN, 51, 97-103.
    • Geraets, A. F. J., Schram, M. T., Jansen, J. F. A., Backes, W. H., Schalkwijk, C. G., Stehouwer, C. D. A., van Boxtel, M. P. J., Eussen, S. J. P. M., Kooman, J. P., Verhey, F. R. J., & Köhler, S. (2022). The cardiometabolic depression subtype and its association with clinical characteristics: The Maastricht Study. Journal of Affective Disorders, 313, 110-117.
    • Baylan, U., Korn, A., Emmens, R. W., Schalkwijk, C. G., Niessen, H. W. M., Krijnen, P. A. J., & Simsek, S. (2022). Liraglutide treatment attenuates inflammation markers in the cardiac, cerebral and renal microvasculature in streptozotocin-induced diabetic rats. European Journal of Clinical Investigation, 52(9), [13807].
    • Zhang, X., Schalkwijk, C. G., & Wouters, K. (2022). Immunometabolism and the modulation of immune responses and host defense: A role for methylglyoxal?Biochimica et Biophysica Acta-Molecular Basis of Disease, 1868(8), [166425].
    • Barutta, F., Bellini, S., Guarrera, S., Matullo, G., Schalkwijk, C., Stehouwer, C. D., Chaturvedi, N., Soedamah-Muthu, S. S., Durazzo, M., & Gruden, G. (2022). Association of Serum MicroRNA-145-5p Levels with Microvascular Complications of Type 1 Diabetes: the EURODIAB Prospective Complications Study. Diabetes Research and Clinical Practice, 190, [109987].
    • Brouwers, M. C. G. J., Simons, N., Kooi, M. E., de Ritter, R., van Dongen, M. C. J. M., Eussen, S. J. P. M., Bekers, O., Kooman, J., van Greevenbroek, M. M. J., van der Kallen, C. J. H., Schram, M. T., Schaper, N. C., Schalkwijk, C. G., & Stehouwer, C. D. A. (2022). Intrahepatic lipid content is independently associated with soluble E-selectin levels: The Maastricht study. Digestive and Liver Disease, 54(8), 1038-1043.
    • Jin, S., Kusters, Y. H. A. M., Houben, A. J. H. M., Plat, J., Joris, P. J., Mensink, R. P., Schalkwijk, C. G., Stehouwer, C. D. A., & van Greevenbroek, M. M. J. (2022). A randomized diet-induced weight-loss intervention reduces plasma complement C3: Possible implication for endothelial dysfunction. Obesity, 30(7), 1401-1410.